The current read
Initial read: constructive on valuation, with the most interesting near-term asymmetry outside menin. Syndax is already a two-product company.
- In 2Q26 it recorded $54.7 million of Revuforj revenue and $18.1 million of Niktimvo collaboration revenue; Niktimvo itself generated $60.3 million of sales at Incyte. Annualizing the $72.8 million reported to Syndax gives approximately $291 million against a derived enterprise value of roughly $1.30 billion, or 4.5x.
- Including the $344 million carrying value of the Royalty Pharma revenue interest raises the bridge to approximately $1.64 billion, or 5.6x. The second is the more conservative presentation because 13.8% of U.S.
- Niktimvo sales is already spoken for until the capped obligation is repaid. The commercial base is credible, but not yet self-funding: guided 2026 R&D plus SG&A is approximately $400 million ex-SBC.
- Cash and investments were $575.1 million at June 30, alongside $250 million of converts; management expects liquidity and growing revenue to fund the company to profitability. Revuforj growth is increasingly duration-led.
- Revenue rose 12% and prescriptions 15% sequentially, with Syndax attributing the quarter primarily to longer treatment after transplant. Roughly half of KMT2A patients proceed to transplant and roughly half have resumed therapy so far.
- Kura's NPM1 share claim attacks only part of this base: more than 30% of 2Q26 Revuforj revenue came from NPM1, while Revuforj remains the only approved menin inhibitor in R/R KMT2A disease and covers patients aged one year and older. Frontline AML is large but distant; early combination data are strong, but randomized EVOLVE-2 and REVEAL-ND must show incremental benefit.
- That makes 4Q26 axatilimab data unusually important. The frontline cGVHD combination readout tests label expansion.
- MAXPIRe is the larger swing, asking whether CSF-1R macrophage modulation can reduce 26-week FVC decline on top of background antifibrotics in IPF. A clean result creates a second disease franchise; a miss leaves a growing commercial base largely intact.